HIGH QUALITY SERVICE

high technology innovation , high speed development.

HIGH QUALITY SERVICE

肺癌 TMA

上海芯超生物科技有限公司 
生物芯片上海国家工程研究中心

上海市高新技術企業

  • 上海芯超生物科技有限公司成立於2003年12月18日
  • 為美國BIOXXX 組織晶片公司之上游供應商

擁有十五863消化道腫瘤組織庫與組織芯片重大項目、十一五863胰腺癌基因組重大項目、衛生部肝癌組織芯片分子標記物篩選重大項目、863胃癌易感基因與幽門螺桿菌耐藥基因聯合檢測重點項目。

商品介紹

Catalog

Diameter

Dots

Cases

Description

HLugA098Bc01

1.0mm

98

55

1. Lung adenocarcinoma 55 cases, 43 cases with mateched normal adjacent tissue. 1 core/case. 30 male cases and 25 female cases.
2. Smoking history available.
3. All cases overlapped with OD-CT-RsLug04-003

HLugA120PG01

1.5mm

120

120

120 cases lung adenocacinoma,1 core/case. Pathology grade  Ⅰ,Ⅱ and Ⅲ.

HLug-Ade030PG-01

2.0mm

30

15

1. Lung adenocarcinoma (15 cases), Tumor (1 core/case) and matched normal adjacent tissue (1 core/case). 
2. Pathology grade 2,3.

HLug-Ade050CD-01

2.0mm

50

36

 Various lung deseases: normal lung tissue,lung adenocarcinoma/normal adjacent tissue(Clinical stage(AJCC 7.0)I  II  III  IV),metastses of lung adenocarcinoma,positive and negative lyphm nodes

HLug-Ade060PG-01

2.0mm

60

30

1. Lung adenocarcinoma (30 cases), tumor (1 core/case) and matched normal adjacent tissue (1 core/case). 
2. Pathology grade 1 (3 cases), 1-2 (2 cases), 2 (15 cases), 2-3 (4 cases), 3 (6 cases). 
3.12 cases have survival information.

HLug-Ade090Lym-01

1.5mm

90

30

1. Lung adenocarcinoma (30 cases), tumor (1 core/case), matched normal adjacent tissue (1 core/case) and matched positive lymph nodes (1 core/case). 
2. Pathology grade 1, 2, 3.

HLug-Ade150CS-01

1.5mm

150

75

1. Lung adenocarcinoma (75 cases), tumor (1 core/dase) and matched normal adjacent tissue (1 core/case).
2. Clinical stage  I, II, III, IIII (Version7.0).
3. 100% cases have TNM detail information.

HLug-Ade150CS-02

1.5mm

150

75

1. Lung adenocarcinoma (75 cases), tumor (1 core/case) and matched normal adjacent tissue (1 core/case).
2. Clinical stage  I(37 cases), II(18 cases), III(16 cases), IIII(4 cases) (Version7.0).
3. 100% cases have TNM detail information.
4. replication of HLug-Ade150CS-01

HLug-Ade150Sur-02

1.5mm

150

75

1. Lung adenocarcinoma (75 cases), tumor (1 core/dase) and matched normal adjacent tissue (1 core/case).
2. Survival information available. Being followed up for 3-5 years.
3. With IHC data of VEGF and survivin.

HLug-Ade180Sur-01

1.5mm

180

90

1.90 cases of lung adenocarcinoma with matched adjacent normal tissue, 1 core/case.
2.Clinical stage(AJCC 7.0)I  II III  IV, with TNM score.
3.43 cases fromHLug-Ade150Sur-01 and HLug-Ade150Sur-02
4.Survival information available. Surgery date 2004.7-2009.6, visit date 2014.8. Being followed up for 5-10 years 

HLugC120PT01

1.5mm

120

60

60 cases of varied kinds of lung carcinoma,tumor(1 core/case) and matched normal adjacent tissue (1 core/case).26 cases adenocarcinoma,14 cases squamous cell carcinoma,7 cases adnosquamous carcinoma,5 cases large cell carcinoma and 8 cases small cell carcinoma

HLugI040PT01

2.0mm

40

40

lung disease 40 cases, 1 core/case:normal lung tissue,pneumonia, inflammatory pseudotumor, pulmonary tuberculosis, pulmonary hamartoma.

HLug-NSCLC150PT-01

1.5mm

150

75

1. Non-small cell lung carcinoma (75 cases), containing adenocarcinoma (30 cases), squamous cell carcinoma (30 cases), bronchio alveolar carcinoma (5 cases), adenosquamous carcinoma (7 cases) and large cell carcinoma (3 cases). 
2. Tumor (1 core/case) and matched normal adjacent tissue (1 core/case).  
3. Pathology grade 1, 2, 3.

HLugS060CD01

2.0mm

60

38

 Various lung deseases: normal lung tissue,lung squamous cell carcinoma/normal adjacent tissue(Clinical stage(AJCC 7.0)I  II  III  IV),metastses of lung  squamous cell carcinoma,positive and negative lyphm nodes.

HLug-Squ030PG-01

2.0mm

30

15

1. Lung squamous cell carcinoma (15 cases), Tumor (1 core/case) and matched normal adjacent tissue (1 core/case). 
2. Pathology grade 2.

HLug-Squ090Lym-01

1.5mm

90

30

1. Lung squamous cell carcinoma (30 cases), tumor (1 core/case), matched normal adjacent tissue (1 core/case) and matched positive lymph nodes (1 core/case).
2. Pathology grade 1-2, 2, 2-3.

HLug-Squ150CS-01

1.5mm

150

75

1. Lung squamous cell carcinoma (75 cases), tumor (1 core/case) and matched normal adjacent tissue (1 core/case).  
2. Clinical stage I (23 cases), II (24 cases), III (23 cases), IV (5 cases).  
3. 100% cases haveTNM detail information.

HLug-Squ150Sur-01

1.5mm

150

75

1. Lung squamous cell carcinoma (75 cases), tumor (1 core/dase) and matched normal adjacent tissue (1 core/case).
2. Survival information available. Being followed up for more than 5 years.
3. With IHC data of VEGF and survivin.

HLug-Squ150Sur-02

1.5mm

150

75

1. Lung squamous cell carcinoma (75 cases), tumor (1 core/dase) and matched normal adjacent tissue (1 core/case).
2. Survival information available. Being followed up for 3-5 years.
3. With IHC data of VEGF and survivin.

OD-CT-RsLug01-003

1.0mm

300

100

1. Small cell lung carcinoma (100 cases), 3 cores/case.

OD-CT-RsLug01-007

1.5mm

120

60

1. Lung carcinoma (60 cases), containing adenocarcinoma (10 cases), squamous cell carcinoma (10 cases), adenosquamous carcinoma (10 cases), large cell carcinoma (10 cases), bronchio alveolar carcinoma (10 cases), small cell carcinoma (10 cases).
2. Tumor (1 core/case) and matched normal adjacent tissue (1 core/case) 
3. Clinical stage I, II, III (Version7.0). 
4.  75% cases have TNM detail information. 
5. 22 cases have survival information.

OD-CT-RsLug01-009

1.5mm

150

75

1. Lung squamous cell carcinoma (75 cases), tumor (1 core/case) and matched normal adjacent tissue (1 core/case).  
2. Clinical stage I (27 cases), II (28 cases), III (18 cases), IV (2 cases). 
3. 100% cases haveTNM detail information.
4. Pathology grade 1, 2, 3.
5. 57 cases have survival information. Visit date 2012.7.

OD-CT-RsLug02-001

2.0mm

32

32

1. Lung squamous cell carcinoma (32 cases), 1 core/case.  
2. Pathology grade 1, 1-2.

OD-CT-RsLug02-002

2.0mm

32

32

1. Lung squamous cell carcinoma (32 cases), 1 core/case.  
2. Pathology grade 2.

OD-CT-RsLug02-004

2.0mm

32

32

1. Lung adenocarcinoma (32 cases), 1 core/case.   
2. Pathology grade 2, 2-3.

OD-CT-RsLug03-002

2.0mm

62

31

1. Lung squamous cell carcinoma (30 cases) and adenocarcinoma (1 case), tumor (1 core/case) and matched normal adjacent tissue (1 core/case).  
2. Clinical stage I, II, III (Version 7.0).  
3. 60% cases have TNM detail information.
4. Pathology grade 1, 2, 3. 
5.18 cases have survival information.

OD-CT-RsLug04-001

1.5mm

92

92

1. Lung squamous cell carcinoma (92 cases), 1 core/case.  
2. Pathology grade 1, 2, 3.

OD-CT-RsLug04-003

1.5mm

108

55

1. Lung adenocarcinoma (55 cases), 53 cases have tumor (1 core/case) and matched normal adjacent tissue (1 core/case),  2 cases have tumor tissue (1 core/case). 
2.  Information of smoking history available.

OD-CT-RsLug04-004

1.5mm

106

53

1. Lung squamous cell carcinoma,  51 cases have tumor (1 core/case) and matched normal adjacent tissue (1 core/case), 1 case has tumor tissue (2 cores).  
2. Lung adenosquamous carcinoma (1 case), 1 core/case.  
3. Information of smoking history available.
4. Pathology grade 2.

OD-CT-RsLug04-005

1.5mm

85

42

1. Non-small cell lung carcinoma (40 cases), containing squamous cell carcinoma (21 cases), lung adenocarcinoma (17 cases), adenosquamous carcinoma (2 cases), 2 cores/case.   
2. Normal adjacent tissue (5 cases), 1 core/case. 
3.TNM score available. 
4. Pathology grade 1, 2, 3.

HLugA090Ly02

1.5mm

90

30

Lung adenocarcinoma (30 cases), tumor (1 core/case), matched NAT (1 core/case) and matched positive lymph nodes (1 core/case).

HLugA180Su02

1.5mm

180

93

1.93 cases of lung adenocarcinoma, 87 cases with matched adjacent normal tissue, 1 core/case.
2.Clinical stage(AJCC 7.0)I  II III  IV, with TNM score.
3.Survival information available. Surgery date 2004.7-2009.6, visit date 2014.8. Being followed up for 5-10 years, same with HLug-Ade180Sur-01

HLugA030PG03

2.0mm

30

30

Lung Adenocarcinoma, 15 cases, tumor  (1 core/case) and matched NAT (1 core/case).  Pathology grade II.